Logo image of NMRA

NEUMORA THERAPEUTICS INC (NMRA) Stock Fundamental Analysis

USA - NASDAQ:NMRA - US6409791000 - Common Stock

1.76 USD
+0.02 (+1.15%)
Last: 9/29/2025, 8:00:02 PM
1.7 USD
-0.06 (-3.41%)
Pre-Market: 9/30/2025, 5:18:00 AM
Fundamental Rating

1

Overall NMRA gets a fundamental rating of 1 out of 10. We evaluated NMRA against 196 industry peers in the Pharmaceuticals industry. While NMRA seems to be doing ok healthwise, there are quite some concerns on its profitability. NMRA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NMRA has reported negative net income.
NMRA had a negative operating cash flow in the past year.
NMRA had negative earnings in each of the past 5 years.
NMRA had a negative operating cash flow in each of the past 5 years.
NMRA Yearly Net Income VS EBIT VS OCF VS FCFNMRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

With a Return On Assets value of -112.63%, NMRA is not doing good in the industry: 77.04% of the companies in the same industry are doing better.
NMRA has a Return On Equity of -137.84%. This is in the lower half of the industry: NMRA underperforms 63.78% of its industry peers.
Industry RankSector Rank
ROA -112.63%
ROE -137.84%
ROIC N/A
ROA(3y)-51.72%
ROA(5y)-52.12%
ROE(3y)-56.07%
ROE(5y)-55.97%
ROIC(3y)N/A
ROIC(5y)N/A
NMRA Yearly ROA, ROE, ROICNMRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NMRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMRA Yearly Profit, Operating, Gross MarginsNMRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, NMRA has more shares outstanding
NMRA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for NMRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
NMRA Yearly Shares OutstandingNMRA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50M 100M 150M
NMRA Yearly Total Debt VS Total AssetsNMRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

NMRA has an Altman-Z score of -5.32. This is a bad value and indicates that NMRA is not financially healthy and even has some risk of bankruptcy.
NMRA has a Altman-Z score of -5.32. This is in the lower half of the industry: NMRA underperforms 60.20% of its industry peers.
NMRA has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.11, NMRA is in line with its industry, outperforming 51.02% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -5.32
ROIC/WACCN/A
WACCN/A
NMRA Yearly LT Debt VS Equity VS FCFNMRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 10.54 indicates that NMRA has no problem at all paying its short term obligations.
NMRA has a Current ratio of 10.54. This is amongst the best in the industry. NMRA outperforms 83.16% of its industry peers.
NMRA has a Quick Ratio of 10.54. This indicates that NMRA is financially healthy and has no problem in meeting its short term obligations.
NMRA's Quick ratio of 10.54 is amongst the best of the industry. NMRA outperforms 83.16% of its industry peers.
Industry RankSector Rank
Current Ratio 10.54
Quick Ratio 10.54
NMRA Yearly Current Assets VS Current LiabilitesNMRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

NMRA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.67%, which is quite impressive.
EPS 1Y (TTM)38.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.76% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y5.67%
EPS Next 2Y15.14%
EPS Next 3Y11.15%
EPS Next 5Y13.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NMRA Yearly Revenue VS EstimatesNMRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B
NMRA Yearly EPS VS EstimatesNMRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2 3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NMRA. In the last year negative earnings were reported.
Also next year NMRA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMRA Price Earnings VS Forward Price EarningsNMRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMRA Per share dataNMRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.14%
EPS Next 3Y11.15%

More info and screens

0

5. Dividend

5.1 Amount

NMRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEUMORA THERAPEUTICS INC

NASDAQ:NMRA (9/29/2025, 8:00:02 PM)

Premarket: 1.7 -0.06 (-3.41%)

1.76

+0.02 (+1.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners54.6%
Inst Owner Change-12.84%
Ins Owners5.41%
Ins Owner Change-0.03%
Market Cap285.03M
Analysts74.29
Price Target7.14 (305.68%)
Short Float %5.46%
Short Ratio7.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.08%
Min EPS beat(2)-10.01%
Max EPS beat(2)12.16%
EPS beat(4)2
Avg EPS beat(4)1.94%
Min EPS beat(4)-13.12%
Max EPS beat(4)18.71%
EPS beat(8)4
Avg EPS beat(8)-27.78%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.27%
EPS NY rev (1m)0.05%
EPS NY rev (3m)-0.47%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB 1.56
EV/EBITDA N/A
EPS(TTM)-1.57
EYN/A
EPS(NY)-1.03
Fwd EYN/A
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-1.21
OCFYN/A
SpS0
BVpS1.13
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -112.63%
ROE -137.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.72%
ROA(5y)-52.12%
ROE(3y)-56.07%
ROE(5y)-55.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.54
Quick Ratio 10.54
Altman-Z -5.32
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1039.1%
Cap/Depr(5y)890.19%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.81%
EPS Next Y5.67%
EPS Next 2Y15.14%
EPS Next 3Y11.15%
EPS Next 5Y13.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year13.72%
EBIT Next 3Y12.91%
EBIT Next 5Y7.21%
FCF growth 1Y-62.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-62.8%
OCF growth 3YN/A
OCF growth 5YN/A